Business Context and Reporting Period
Company: Psyence Biomedical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Filed: January 8, 2026
Reporting Period: This filing serves as a notice for the Annual General and Special Meeting of Shareholders scheduled for January 22, 2026. It references financial statements for the years ended March 31, 2025 and 2024, and unaudited condensed statements for the three and six months ended September 30, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Management Information Circular (Exhibit 99.1) but are not detailed in the cover document itself.
Material Changes
No material changes to financial performance or operations are described in this specific filing text. The document functions as a procedural notice to distribute financial reports and meeting materials rather than a report of new operational developments.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a Management Information Circular containing the Management Discussion and Analysis (MD&A) for the referenced periods.
Outlook: No specific forward-looking guidance is provided in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover letter; investors are directed to the full MD&A in Exhibit 99.1 for such information.
Investor Verification Checklist
- Verify the full content of the Management Information Circular (Exhibit 99.1) for detailed financial results.
- Review the Consolidated Financial Statements for the years ended March 31, 2025 and 2024.
- Examine the Unaudited Condensed Consolidated Financial Statements for the periods ended September 30, 2025 and 2024.
- Confirm the agenda and voting matters for the Annual General Meeting on January 22, 2026.